Trial Profile
PHASE II STUDY OF SUNITINIB AS RECHALLENGE THIRD-LINE THERAPY IN METASTATIC RENAL CANCER [Studio di fase II con rechallenge di Sunitinib come trattamento di terza linea nel carcinma renale metastatico]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jun 2017
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 06 Jun 2017 Primary endpoint (Disease progression rate (To assess the antitumor activity of Sunitinib in terms of freedom from disease progression.)) has been met as per the results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 25 Jan 2017 Status changed from recruiting to completed.